2nd Aseptic BioPharma Processing Summit
November 9-10, 2023
Vienna, Austria
ABOUT THE EVENT
Staying updated on regulatory requirements is crucial for ensuring compliance and maintaining the highest quality standards in drug manufacturing. The new EU GMP Annex 1 is officially published and will take effect in August 2023. How to deal with new challenges, adopt new methods aligning with stricter standards and embrace new innovative technologies?
Our 2nd edition of the Aseptic BioPharma Processing Summit features comprehensive coverage on the implementation and management of the latest knowledge in aseptic, barrier, containment, and aseptic best practice technologies along with environmental monitoring systems, facility cleaning and disinfectant qualification, cleanroom operations, filtration, sterilization, and aseptic process simulation or media fill. This two-day summit encompasses expert insight into the robust aseptic processing requirements facing the industry as well as delving into more focus on the ever-growing rise of advanced therapies from allogenic cell therapies to innovative fill-finish lines.
Come and join us in Vienna this November 9-10 together with manufacturers, regulators, and experts for the industry’s collective knowledge, gain different perspectives, and foster innovation in aseptic pharmaceutical manufacturing.
CONFERENCE LEARNING POINTS
- Overview of new EU GMP Guidelines and Annex 1
- Cleanroom design and environmental monitoring
- Optimization of fill finish operations
- Novel technologies for rapid sterilization and
decontamination - Automation and robotics in pharmaceutical production
- Single-use systems in aseptic manufacturing
- New developments in lyophilization and automatic
vial loading/unloading - Developing a holistic aseptic training program
SPEAKERS
As a member of our team, you’ll help deliver on our mission to strive for better health and a brighter future for people worldwide through leading innovation in medicine. It’s a responsibility that motivates and inspires us all.
You’ll find your own professional inspiration at Takeda, in the area that suits your interests and skills. Whether that’s R&D, Oncology, Corporate, Manufacturing, Quality, or another business unit, wherever you find yourself at Takeda, you’ll enjoy a meaningful career that’s making a positive impact on patients, people and the planet.
With over 1200 employees, the Fraunhofer Institute for Manufacturing Engineering and Automation IPA (Fraunhofer IPA) is one of the largest institutes in the Fraunhofer-Gesellschaft. The total budget amounts to € 90 million. The institute’s research focus is on organizational and technological aspects of production. We develop, test and implement not only components, devices and methods, but also entire machines and manufacturing plants. Our 19 departments are coordinated via six business units, which together conduct interdisciplinary work with the following industries: automotive, machinery and equipment industry, electronics and microsystems, energy, medical engineering and biotechnology as well as process industry. The research activities of Fraunhofer IPA aim at the economic production of sustainable and personalized products.
Our Purpose is to push the boundaries of science to deliver life-changing medicines. We believe the best way we can achieve our Purpose is to put science at the centre of everything we do. Science defines who we are. It is why we come to work every day and is part of our DNA. But this is only half of the story. We know that we do not have all the answers. We want to share ideas because we believe it results in better medicines. We want the way we work to be inclusive, open and collaborative. This approach runs through all that we do.
We focus on three main therapy areas – Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory – and we are also selectively active in the areas of autoimmunity, neuroscience and infection. To put ourselves in the best position to push the boundaries of science, we seek to leverage our combination of capabilities, which encompass both small molecules and biologics, and include immunotherapies and developing innovative delivery devices that can offer choice to patients. These are reinforced by a strong focus on personalised healthcare capabilities, which aim to match medicines only to those patients who will benefit from them. Our teams also work alongside the world’s leading academic and biotech research institutions to stimulate innovation and evaluate emerging technologies such as Modified RNA and CRISPR genome editing.
Programs at Polpharma Biologics start in cell line development and transition through technical and clinical development to commercial-scale production preparing drugs for future commercial partnerships with global pharmaceutical players. The company’s expertise is in the development and manufacturing of medicines based on microbial and mammalian expression systems.
As a member of our team, you’ll help deliver on our mission to strive for better health and a brighter future for people worldwide through leading innovation in medicine. It’s a responsibility that motivates and inspires us all.
You’ll find your own professional inspiration at Takeda, in the area that suits your interests and skills. Whether that’s R&D, Oncology, Corporate, Manufacturing, Quality, or another business unit, wherever you find yourself at Takeda, you’ll enjoy a meaningful career that’s making a positive impact on patients, people and the planet.
Today, CSL – including our businesses, CSL Behring, CSL Seqirus, CSL Plasma and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs 32,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest.
When it comes to new ideas and innovations, we don’t leave anything to chance. We work with our customers to ensure that we are always one decisive, innovative step ahead of the competition, even for niche products. This is how we create great things such as complete turnkey lines. Yet, in small things, we are unbeatable: As the technology leader, we set the standards for dosing powder in even the tiniest of quantities and for the most delicate of assembly processes.
PLIVA’s production portfolio includes a high number of finished dosage forms covering almost all therapeutic groups and active pharmaceutical ingredients. Focused on development of generic and niche products, PLIVA has the broadest portfolio of generic medicines in Central and Eastern Europe.
MEDIA PARTNERS
VENUE
NH VIENNA AIRPORT
EINFAHRTSSTRAßE 1-3,
1300 Schwechat
More details:
Tel:+49 30 2238 0233
Email: events@nh-hotels.com